Heterobifunctional protein degraders, such as PROteolysis TArgeting Chimera (PROTAC)
protein degraders, constitute a novel therapeutic modality that harnesses the cell's natural …

Hormonal therapy plays a vital part in the treatment of estrogen receptor–positive (ER+)
breast cancer. ER can be activated in a ligand-dependent and independent manner …

Targeted protein degradation (TPD) is one of the key strategies of current targeted cancer
therapy, and it can eliminate some of the root causes of cancer, and effectively avoid drug …

CDK12 is a cyclin-dependent kinase that plays critical roles in DNA replication, transcription,
mRNA splicing, and DNA damage repair. CDK12 genomic changes, including mutation …

ABSTRACT Introduction Molecular Glue Degraders (MGDs) is a concept that refers to a
class of compounds that facilitate the interaction between two proteins or molecules within a …

Protein–protein interactions (PPIs) play a fundamental role in various biological functions;
thus, detecting PPI sites is essential for understanding diseases and developing new drugs …

The evolution of cancer treatment has provided increasingly targeted strategies both in the
upfront and relapsed disease settings. Small‐molecule inhibitors and immunotherapy have …

Despite successes with new drug approvals over the past two decades through
conventional drug development approaches, many human diseases remain intractable to …

Annual breast cancer (BCa) deaths have declined since its apex in 1989 concomitant with
widespread adoption of hormone therapies that target estrogen receptor alpha (ERα), the …

The global spread of severe acute respiratory syndrome corona virus-2 (SARS-CoV-2)
variants is alarming. In addition to vaccines, effective antiviral agents are urgently needed to …